Biocon Biologics to Acquire Viatris' (VTRS) Biosimilars Assets for up to $3.335 billion in Stock and Cash

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BE
8. FIX
9. NDAQ
10. TSCO

Go back to Biocon Biologics to Acquire Viatris' (VTRS) Biosimilars Assets for up to $3.335 billion in Stock and Cash

Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

February 28, 2022 8:41 AM EST

BENGALURU, India, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris' biosimilars business to create a unique fully integrated global biosimilars enterprise. The revenues of this acquired business are estimated to be USD 1 billion next year. Viatris will receive consideration of up to USD 3.335 billion in cash and stock.

... More